Servier acquires BN 104 for Leukemia

Servier and BioNova Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, announce that the companies have entered into a definitive agreement under which Servier will acquire BN 104, a potential best-in-class menin inhibitor currently in Phase I/II development for the treatment of acute leukemias. In line with its 2030 strategy, Servier aims to accelerate the global clinical development of BN104 in mutated AML as well as acute lymphoblastic leukemia (ALL) where the unmet medical need is high, especially for safer therapies in relapse/refractory conditions. This asset will enable Servier to further expand its hematological oncology franchise and build on its leadership with a targeted and differentiated portfolio of medicines in this field. Under the terms of the agreement, BioNova Pharmaceuticals will receive a cash payment for its sale of BN 104 with development and regulatory earn-outs. The transaction is subject to customary closing conditions.